Investor's Business Daily on MSN
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed its early losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention ...
Nearly 40 years after HIV was first identified, the virus continues its devastating march across the globe. Today, 38 million people live with HIV, and each year brings 1.5 million new infections and ...
For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Ten years ago, the Indiana community of Austin made headlines for its historic HIV outbreak brought on by intravenous drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback